Botanix Pharmaceuticals Limited
BXPHF
$0.099
-$0.001-1.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 210.96% | 205.18% | -0.16% | 2.26% | 2,715.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 210.96% | 205.18% | -0.16% | 2.26% | 2,715.15% |
| Cost of Revenue | -6.83% | -8.56% | 23.53% | 26.41% | 314.44% |
| Gross Profit | 381.87% | 376.63% | -38.45% | -41.68% | -67.89% |
| SG&A Expenses | 589.82% | 576.89% | 510.45% | 524.69% | 139.23% |
| Depreciation & Amortization | 1,639.34% | 1,603.32% | 13,392.59% | 13,278.57% | -32.59% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 439.35% | 429.24% | 447.84% | 460.63% | 119.08% |
| Operating Income | -484.97% | -474.03% | -478.46% | -491.97% | -85.00% |
| Income Before Tax | -542.17% | -530.15% | -464.91% | -478.11% | -81.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -542.17% | -530.15% | -464.91% | -478.11% | -81.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -542.17% | -530.15% | -464.91% | -478.11% | -81.91% |
| EBIT | -484.97% | -474.03% | -478.46% | -491.97% | -85.00% |
| EBITDA | -476.19% | -465.40% | -459.10% | -472.15% | -84.02% |
| EPS Basic | -427.78% | -416.67% | -358.33% | -375.00% | -50.00% |
| Normalized Basic EPS | -436.36% | -427.27% | -337.50% | -350.00% | -57.14% |
| EPS Diluted | -427.78% | -416.67% | -358.33% | -375.00% | -50.00% |
| Normalized Diluted EPS | -436.36% | -427.27% | -337.50% | -350.00% | -57.14% |
| Average Basic Shares Outstanding | 19.73% | 19.73% | 26.29% | 26.29% | 21.62% |
| Average Diluted Shares Outstanding | 19.73% | 19.73% | 26.29% | 26.29% | 21.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |